对于中等心血管风险的个体,使用静止剂治疗
Joongmin Kim1, Hyeongsoo Kim2, Sang Hyun Park3
1Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Metabolism: clinical and experimental
|November 5, 2023
概括
在他类药物治疗后达到低密度脂蛋白胆固醇 (LDL-C) 水平低于120 mg/dL,可显著降低中等风险个体心血管事件风险. 这一发现为管理这一群体中胆固醇目标提供了关键指导.
科学领域:
- 心脏病学 心脏病学
- 公共卫生 公共卫生
- 药理学 药理学是指药理学的学科.
背景情况:
- 中级心血管风险个体构成一个重要的人口部分.
- 确定最佳胆固醇目标对于这个群体来说至关重要.
- 这项研究侧重于在他类药物治疗后的最佳低密度脂蛋白胆固醇 (LDL-C) 水平.
研究的目的:
- 为了研究最佳的低密度脂蛋白胆固醇 (LDL-C) 水平在中间心血管风险的个人后,他类药物治疗.
- 为这一群体提供基于证据的胆固醇管理建议.
- 分析治疗后的LDL-C水平与心血管事件之间的关联.
主要方法:
- 全国范围的观察和验证队列研究利用韩国国家健康保险服务和医院数据.
- 纳入标准:中等心血管风险 (≥2个风险因素,不包括糖尿病),LDL-C 100-189 mg/dL,新使用他类药物.
- 主要结局:复合心血管事件 (心肌梗塞,冠状动脉再血管化,缺血性中风);随访时间:7.5-8.7年.
主要成果:
- 在主要队列中,较低的LDL-C水平 (<120 mg/dL) 与心血管综合事件风险降低有关 (p=0.001-0.009).
- 在验证队列中,LDL-C<100 mg/dL显示出更明显的降低风险 (p=0.006-0.03).
- 总死亡风险在LDL-C组之间没有显著差异.
结论:
- 达成LDL-C水平<120 mg/dL后的状态类药物治疗与中等风险个体中较低的心血管事件风险有关.
- 这些发现支持<120 mg/dL作为该人群有益的LDL-C目标.
- 这项研究为优化他类药物治疗和胆固醇管理提供了临床相关的见解.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
674
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
674
01:26Atherosclerosis III: Management
11
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
11
01:27Coronary Artery Disease V: Interprofessional Care
9
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
9
01:28Acute Coronary Syndrome IV: Interprofessional Care
11
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
11
01:27Peripheral Artery Disease III: Interprofessional Care
11
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
11
01:26Angina IV: Management
9
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
9